To the best of our knowledge, no indication on the effect of AMPs on the expression of airway epithelia-associated genes upon their administration to infected or non-infected lungs has been provided so far. This is a fundamental issue that deserves to be investigated in order to explore the clinical safety of a new drug. Indeed, besides experiencing the AMPs effect on the bacterial clearance, it is also meaningful to get insight into their potential beneficial/toxic effect on the lung epithelium, in vivo.